SGLT-2 inhibitors reduce cardiovascular deaths, heart failure hospitalizations, hyperkalemia, and decline of renal function in patients with HFrEF.
Sunjeev Konduru, PharmD, MS, BCPS
Advertisement
Articles by Sunjeev Konduru, PharmD, MS, BCPS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
2
FDA Approves First Drug for Pediatrics With Irritable Bowel Syndrome With Constipation
3
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
4
Regular Melatonin Supplementation May Hide Hidden Heart Complications
5
